ReviewCurrent oncology reports2014
Advances in the management of paediatric high-grade glioma.
Review in Current oncology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Posttreatment DSC-MRI is Predictive of Early Treatment Failure in Children with Supratentorial High-Grade Glioma Treated with Erlotinib.Clinical neuroradiology · 2018Trial
- Rare regression of congenital brainstem high-grade glioma: case report and literature review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Review
- Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma.Frontiers in pharmacology · 2023Review
- Indisulam Reduces Viability and Regulates Apoptotic Gene Expression in Pediatric High-Grade Glioma Cells.Biomedicines · 2022Article
- Article
- Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer.Cancer biology & therapy · 2018Article
- Commentary on: "A Multi-Institutional Experience in Pediatric High Grade Glioma".Frontiers in oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-grade gliomas represent a formidable challenge to paediatric oncologists. The second most common malignant brain tumour of childhood, little progress has been made in the outcome of these tumours in the last four decades. Outcome remains dire with less than 20% of patients surviving. Current treatment consists of maximal resection and radiotherapy, with chemotherapy both in conjunction with and adjuvant to radiotherapy being added more recently. Yet much of the evidence for the use of chemotherapy is extrapolated from adult data, and evidence for its use in the paediatric population is weak. Recent advances in the biology of high-grade glioma in children identify epigenomic subgroups distinct from those seen in adults, suggesting a separate tumourigenic mechanism and delineating a separate disease entity. The time may be to move forward with a different way of thinking about paediatric tumours. With biological insight comes the promise of more effective therapies, rationally targeted towards the biology of the tumour. This review addresses the current advances in paediatric high-grade glioma and how we can move forward to translate this into improved outcomes for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.